Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.